আরশোলাদের ঠেকাতে দিল্লির সুন্দর রাস্তাকেই নোংরা করতে হচ্ছে!😃😂 এমন অভিনব বুদ্ধি কার মাথা থেকে বেরোল, সেটা জানার কৌতূহল হচ্ছে! 🤔🤣
প্রতিবাদ ঠেকাতে গিয়ে যদি রাস্তারই এই অবস্থা হয়, তাহলে এদের জ্ঞান-বুদ্ধি নিয়ে প্রশ্ন ওঠাটাই স্বাভাবিক!😊🙄
JD Vance describes HIB professionals as “indentured servants”.
That’s an emotive word to use - given India’s history with indenture during the British Empire.
Government of India restricted @abhijeet_dipke’s video on X almost immediately after it was posted.
This is the video the Government of India doesn’t want you to see.
https://t.co/Ax7SSsFjVL
@sagarikaghose All the morons criticising the voices of dissent do not understand democracy. Arundhati Roy may not say what you like but she has a right & for that she can’t be called an urban naxal, librandu etc. Foul mouth seems to be the terminal symptom of extreme right wingism - tc ppl.
@RahulGandhi Don’t shy away from taking up the role of #leaderofopposition & building on the credibility you garnered. Any laxity or laziness now would dilute your brand equity and hence the chances of @INCIndia forming the government in 2029
@adityasvlogs@pbhushan1 you will never get it @aditya As a monotheist, you’re conditioned not to see beyond your God and his party or to accept the fact that people showed Modi his place. #INC deserves way more credit in this election than #BJP .
@KarunaGopal1 BJP is just like any other party- happy to host turncoats and criminals if they profess their loyalty (& MONEY). All I can say is party ideologues everywhere are just a dying breed.
@sagarikaghose Pardon the mo(o)dhbhakt gangs that’re trolling you and rajdeep…. They just don’t know what they’re saying or doing as they’ve sold their heart, brain and soul to communalism & filled those holes with dark and intense love for a certain Modi - they are just sick and suffering…..
Many people might be unaware of the history behind the OAI status that the US FDA granted to an ex-Phalanx facility. When @LaurusLabs acquired the Phalanx intermediates facility (in 2020), it was already on the banned list of the US FDA (2016 public news link that anyone could have googled after Laurus disclosed the acquisition in their 2020–2021 annual report).
https://t.co/4wHDsl8Tbg
Laurus, as we know, has had a clean track record with the US FDA and other stringent regulators for years now, and all this data is publicly available on the US FDA and other websites. Previous US FDA audits have had NAI or VAI status (see second image attached).
Needless to say, Laurus was aware that the US FDA would take into account the entire "history and geography" of the facility starting in 2016, when Laurus did not own it. An anti-fragile leadership is one who can buy a sick unit with plenty of room for expansion and get it approved for future use (we saw that with Neuland Unit 3 acquisition, though it was not under an import alert when Neuland bought it from Arch Labs around 2017).
I have every reason to believe that Team Laurus will fix the non-compliance history of this ex-Phalanx facility and get to VAI/NAI status in the future. Let things play out over time. From the pre-acquisition import alert in 2016 to OAI status today, itself, is a progression.
The size of the plant is very small, and the revenue contribution from this facility is less than 1%, and that too includes some HIV intermediates. Any company that can transform from a single domain (ARV) to many complex domains, including enzymes, biotechnology, and the next generation of precision medicines (cell and gene therapy), and is on the cusp of a massive CDMO transformation (proof of pudding is in eating and true colours of CDMO scale-up will be seen starting H2 of this fiscal). There is a clear "China Minus" sentiment, as I have been highlighting since last year. I explained why China is fragile in my recent engagements (uTube recording is available). CDMO scale-up and growth in India from FY25 to FY30 have the potential to surprise the bulls, let alone the naysayers. I know what I am saying, as I've done my research. Conviction and patience is always a function of self-awareness. Here are some recent tweets on China minus:
https://t.co/Bp79BeSmOb
https://t.co/FAqWwax7gj
Companies like Neuland, Divis, Syngene, Laurus, Glenmark Life, Suven Pharma, Jubilant Pharmova, Jubilant Ingrevia, Piramal Pharma, Kopran, SMS Pharma, Supriya Life and several unlisted ones from Sai Life to Aurigene CDMO will eventually benefit from this very sustainable tailwind, per my industry interactions. My short interaction with DRL chairman last year confirmed very strong traction for #Aurigene. I have no exposure to DRL as a disclosure.
We, a family and friends union consisting of nearly 20 individuals, have invested in Laurus and several other CDMO/API assets worldwide. We know our risk-reward exposure and our holding periods are unusually high, with many assets, such as Neuland, sitting in our portfolios for over 20 years now. Laurus, of course, is a relatively recent entry in that context (invested since December 13, 2019).
Disclaimer: We have no business advising or recommending what you should or should not do. CDMO is a mega-trend, and this is not news to those who have followed me over the years. I have been very vocal about the long-term potential of this industry. Having said that, we may change our stance tomorrow, so follow your own heart, brain, gut, and whatever else. Do your due diligence. It's your money and your risk-reward. Your financial goals, not mine!
That's all. Thank you.
Many people might be unaware of the history behind the OAI status that the US FDA granted to an ex-Phalanx facility. When @LaurusLabs acquired the Phalanx intermediates facility (in 2020), it was already on the banned list of the US FDA (2016 public news link that anyone could have googled after Laurus disclosed the acquisition in their 2020–2021 annual report).
https://t.co/4wHDsl8Tbg
Laurus, as we know, has had a clean track record with the US FDA and other stringent regulators for years now, and all this data is publicly available on the US FDA and other websites. Previous US FDA audits have had NAI or VAI status (see second image attached).
Needless to say, Laurus was aware that the US FDA would take into account the entire "history and geography" of the facility starting in 2016, when Laurus did not own it. An anti-fragile leadership is one who can buy a sick unit with plenty of room for expansion and get it approved for future use (we saw that with Neuland Unit 3 acquisition, though it was not under an import alert when Neuland bought it from Arch Labs around 2017).
I have every reason to believe that Team Laurus will fix the non-compliance history of this ex-Phalanx facility and get to VAI/NAI status in the future. Let things play out over time. From the pre-acquisition import alert in 2016 to OAI status today, itself, is a progression.
The size of the plant is very small, and the revenue contribution from this facility is less than 1%, and that too includes some HIV intermediates. Any company that can transform from a single domain (ARV) to many complex domains, including enzymes, biotechnology, and the next generation of precision medicines (cell and gene therapy), and is on the cusp of a massive CDMO transformation (proof of pudding is in eating and true colours of CDMO scale-up will be seen starting H2 of this fiscal). There is a clear "China Minus" sentiment, as I have been highlighting since last year. I explained why China is fragile in my recent engagements (uTube recording is available). CDMO scale-up and growth in India from FY25 to FY30 have the potential to surprise the bulls, let alone the naysayers. I know what I am saying, as I've done my research. Conviction and patience is always a function of self-awareness. Here are some recent tweets on China minus:
https://t.co/Bp79BeSmOb
https://t.co/FAqWwax7gj
Companies like Neuland, Divis, Syngene, Laurus, Glenmark Life, Suven Pharma, Jubilant Pharmova, Jubilant Ingrevia, Piramal Pharma, Kopran, SMS Pharma, Supriya Life and several unlisted ones from Sai Life to Aurigene CDMO will eventually benefit from this very sustainable tailwind, per my industry interactions. My short interaction with DRL chairman last year confirmed very strong traction for #Aurigene. I have no exposure to DRL as a disclosure.
We, a family and friends union consisting of nearly 20 individuals, have invested in Laurus and several other CDMO/API assets worldwide. We know our risk-reward exposure and our holding periods are unusually high, with many assets, such as Neuland, sitting in our portfolios for over 20 years now. Laurus, of course, is a relatively recent entry in that context (invested since December 13, 2019).
Disclaimer: We have no business advising or recommending what you should or should not do. CDMO is a mega-trend, and this is not news to those who have followed me over the years. I have been very vocal about the long-term potential of this industry. Having said that, we may change our stance tomorrow, so follow your own heart, brain, gut, and whatever else. Do your due diligence. It's your money and your risk-reward. Your financial goals, not mine!
That's all. Thank you.